Detail akcie Swe Orphan Biovitru online

Business Summary: Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Swedish Orphan Biovitrum AB (publ) revenues increased 18% to SEK22.12B. Net income applicable to common stockholders decreased 9% to SEK2.41B. Revenues reflect Immunology - Gamifant segment increase of 84% to SEK1.65B, Haematology-Elocta segment increase of 12% to SEK4.92B, Undetermined Geography segment increase of 90% to SEK2.72B, Europe segment increase of 14% to SEK8.51B.